Kiniksa Pharmaceuticals International, plc (KNSA) Profit Margins
Over the twelve months to 2026-06-30, Kiniksa Pharmaceuticals International, plc (KNSA) had gross margin 89.8%, operating margin 11.9%, net margin 9.6%, free cash flow margin 21.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
KNSAKiniksa Pharmaceuticals International, plcFollow KNSA — free
—
Price chart with a free account
- Market cap
- 6.0B
- P/E TTM
- 78.3
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 26 Oct, in 2 days
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Gross margin | 76.4% | 89.6% | 87.6% | 85.6% | 88.5% | 89.8% | |
| Operating margin | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% | 11.9% | |
| Net margin | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% | 9.6% | |
| FCF margin | -328.7% | 2.6% | 4.9% | 6.0% | 20.1% | 21.7% |
USD millions · SEC XBRL
Kiniksa Pharmaceuticals International, plc — questions
- What is Kiniksa Pharmaceuticals International, plc's gross margin?
- 89.8% over the twelve months to 2026-06-30.
- What is Kiniksa Pharmaceuticals International, plc's operating margin?
- 11.9% over the twelve months to 2026-06-30.
- What is Kiniksa Pharmaceuticals International, plc's net profit margin?
- 9.6% over the twelve months to 2026-06-30.
Every figure on this page comes from Kiniksa Pharmaceuticals International, plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.